vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

vTv Therapeutics (VTVT) granted stock options to purchase 2,500 shares of common stock to a non-executive employee as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

vTv Therapeutics (VTVT) granted stock options to purchase 2,500 shares of common stock to a non-executive employee as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $31.44 per share, a 10-year term, and vest over 4 years, with 25% vesting on the one-year anniversary of the vesting commencement date and the remainder vesting quarterly over the following 36 months, subject to continued employment. The grant is made under the company’s 2026 Inducement Plan and a related stock option agreement. vTv is a late-stage biopharmaceutical company whose lead candidate, cadisegliatin (TTP399), is in a US Phase 3 trial for type 1 diabetes and has FDA Breakthrough Therapy designation.

Market Context

On Aug 19, vTv disclosed a comparable 2,500-option inducement grant; the recorded 24-hour reaction w...

Analysis

On Aug 19, vTv disclosed a comparable 2,500-option inducement grant; the recorded 24-hour reaction was 0.56%, providing a directly comparable precedent for today’s similarly structured employee award.

Key Figures

Stock options granted: 2,500 options Exercise price: $31.44 per share Vesting period: 4 years +3 more

Stock options granted

2,500 options

Non-executive employee inducement grant

Exercise price

$31.44 per share

Option grant

Vesting period

4 years

Subject to continued employment

Initial vesting

25% of shares

Vests on the one-year anniversary

Remaining vesting

36 months

Quarterly vesting after the first anniversary

Option term

10 years

Term of each option award

Historical Context

3 past events · Latest: Aug 19

3 events

1. Aug 19

   Inducement option grant

   24h Move

   +0.6%

   Granted 2,500 options to a non-executive employee under the 2026 Inducement Plan.

2. Jul 28

   Inducement option grants

   24h Move

   +1.3%

   Granted 23,500 options to two employees under Nasdaq inducement provisions.

3. Jul 02

   Inducement option grants

   24h Move

   -2.4%

   Granted 12,500 options to two non-executive employees under the inducement plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), inducement plan, glucokinase activator, breakthrough therapy designation

4 terms

nasdaq listing rule 5635(c)(4) regulatory

"as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement plan financial

"subject to the terms and conditions of the 2026 Inducement Plan"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

glucokinase activator medical

"a potential first-in-class oral glucokinase activator"

A glucokinase activator is a drug that boosts the activity of glucokinase, an enzyme that helps the liver and pancreas sense and lower blood sugar. Think of it as turning up the sensitivity of the body’s sugar thermostat so insulin release and sugar storage respond more effectively; for investors, these drugs matter because they can become new diabetes treatments with sizable market potential while carrying typical development, safety and regulatory risks that affect a company’s value.

breakthrough therapy designation regulatory

"has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration"

A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HIGH POINT, N.C., Sept. 15, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options that were granted at an exercise price of $31.44 per share. Each option award will vest over a 4-year period, with 25% of the shares underlying the option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting quarterly over the following 36 months, subject to continued employment with vTv on such vesting dates. The options have a term of 10 years and are subject to the terms and conditions of the 2026 Inducement Plan and the stock option agreement covering the grant.

About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a US Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.

About Cadisegliatin
Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the US as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin acted selectively on the liver and increased the activity of glucokinase independently from insulin. These studies support clinical investigation of whether cadisegliatin can improve glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).

Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.

Investor Contact
John Fraunces
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com

Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com